Tofé Victoria I, Bagán Leticia, Bagán José V
Oral Medicine, University of Valencia, Spain.
Oral Medicine of the University of Valencia, Department of Stomatology and Maxillofacial Surgery, University of Valencia, General University Hospital, Valencia, Spain.
J Clin Exp Dent. 2020 Jul 1;12(7):e676-e681. doi: 10.4317/jced.57019. eCollection 2020 Jul.
The objective of this study was to describe the clinical and radiographic characteristics of our series of medication-related osteonecrosis of the jaws (ONJ) associated with denosumab.
We presented 15 cases of ONJ associated with denosumab; 11 received treatment for their osteoporosis and four for cancer treatments. We recorded the most frequent clinical findings, symptoms and radiographic characteristics in our patient group, as well as local and systemic contributing factors.
The mean time of treatment with denosumab was 23.83 ± 12.84 months. 40% of the patients had a previous history of treatment with bisphosphonates. The most common local factor was tooth extraction (11 cases; 73.3%), and in most cases there was necrotic bone exposure (13/15, 86.67%). Osteolysis, bone sclerosis and cortical erosion were the most common radiographic findings. Stage 1 was the most frequent, present in 60% of the cases.
In our patient group, most were in the early stages of ONJ. Denosumab, osteonecrosis, jaws, radiology.
本研究的目的是描述我们系列中与地诺单抗相关的颌骨药物性骨坏死（ONJ）的临床和影像学特征。
我们呈现了15例与地诺单抗相关的ONJ病例；其中11例接受骨质疏松治疗，4例接受癌症治疗。我们记录了患者组中最常见的临床发现、症状和影像学特征，以及局部和全身的促成因素。
地诺单抗治疗的平均时间为23.83±12.84个月。40%的患者既往有双膦酸盐治疗史。最常见的局部因素是拔牙（11例；73.3%），且大多数病例存在坏死骨暴露（13/15，86.67%）。骨质溶解、骨硬化和皮质侵蚀是最常见的影像学表现。1期最为常见，占病例的60%。
在我们的患者组中，大多数处于ONJ的早期阶段。地诺单抗、骨坏死、颌骨、放射学。
